Sunho Biologics, Inc. (02898.HK)

Sunho Biologics, Inc. is a holding company, which engages in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The company is headquartered in Huzhou, Zhejiang and currently employs 128 full-time employees. The company went IPO on 2024-05-24. The firm is also engaged in the discovery, development and commercialization of biologics that modulate the immune microenvironment by directly modulating the innate and adaptive immune systems. The firm has three core products, namely IAH0968, IAP0971 and IAE0972. IAH0968 is an antibody-dependent cell-mediated cytotoxicity-enhancing monoclonal antibody. IAP0971 and IAE0972 are both antibody cytokines.